{"id":"NCT00256854","sponsor":"GlaxoSmithKline","briefTitle":"Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome)","officialTitle":"A 4-Week, Randomized, Double-Blind, Cohort Study to Evaluate the Safety and Tolerability of Converting From Ropinirole Immediate Release (IR) to Ropinirole Controlled Release for RLS (CR-RLS) Formulation (Formerly Ropinirole Extended Release [XR]) in Patients With Restless Legs Syndrome (RLS)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-11-14","primaryCompletion":"2006-09-21","completion":"2006-09-21","firstPosted":"2005-11-22","resultsPosted":"2019-03-15","lastUpdate":"2019-03-15"},"enrollment":135,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":null,"primaryPurpose":"TREATMENT"},"conditions":["Restless Legs Syndrome","Restless Legs Syndrome (RLS)"],"interventions":[{"type":"DRUG","name":"Ropinirole IR 1 mg","otherNames":["ropinirole controlled-release for RLS"]},{"type":"DRUG","name":"Ropinirole IR 2 mg","otherNames":[]},{"type":"DRUG","name":"Ropinirole IR 1 mg Placebo","otherNames":[]},{"type":"DRUG","name":"Ropinirole IR 2 mg Placebo","otherNames":[]},{"type":"DRUG","name":"Ropinirole CR 2 mg","otherNames":[]},{"type":"DRUG","name":"Ropinirole CR 3 mg","otherNames":[]},{"type":"DRUG","name":"Ropinirole CR 2 mg Placebo","otherNames":[]},{"type":"DRUG","name":"Ropinirole CR 3 mg Placebo","otherNames":[]}],"arms":[{"label":"Ropinirole cohort A1: 1 mg IR/2 mg CR-RLS/1 mg IR/1 mg IR","type":"EXPERIMENTAL"},{"label":"Ropinirole cohort A2: 1 mg IR/1 mg IR/1 mg IR/2 mg CR-RLS","type":"EXPERIMENTAL"},{"label":"Ropinirole cohort B1: 2 mg IR/3 mg CR-RLS/2 mg IR/2 mg IR","type":"EXPERIMENTAL"},{"label":"Ropinirole cohort B2: 2 mg IR/2 mg IR/2 mg IR/3 mg CR-RLS","type":"EXPERIMENTAL"},{"label":"Ropinirole cohort C1: 4 mg IR/6 mg CR-RLS/4 mg IR/4 mg IR","type":"EXPERIMENTAL"},{"label":"Ropinirole cohort C2: 4 mg IR/4 mg IR/4 mg IR/6 mg CR-RLS","type":"EXPERIMENTAL"}],"summary":"This is a multi-center, Phase III study to evaluate the safety and tolerability of proposed dose conversion recommendations for RLS subjects converting from ropinirole immediate release to ropinirole controlled-release for RLS.","primaryOutcome":{"measure":"Number of Participants With Adverse Events (AEs) Post-conversion From Ropinirole IR to Ropinirole CR Over Period","timeFrame":"Up to 5 weeks","effectByArm":[{"arm":"Ropinirole Cohort A1: 1 mg IR/2 mg CR-RLS/1 mg IR/1 mg IR","deltaMin":9,"sd":null},{"arm":"Ropinirole Cohort A2: 1 mg IR/1 mg IR/1 mg IR/2 mg CR-RLS","deltaMin":14,"sd":null},{"arm":"Ropinirole Cohort B1: 2 mg IR/3 mg CR-RLS/2 mg IR/2 mg IR","deltaMin":10,"sd":null},{"arm":"Ropinirole Cohort B2: 2 mg IR/2 mg IR/2 mg IR/3 mg CR-RLS","deltaMin":11,"sd":null},{"arm":"Ropinirole Cohort C1: 4 mg IR/6 mg CR-RLS/4 mg IR/4 mg IR","deltaMin":7,"sd":null},{"arm":"Ropinirole Cohort C2: 4 mg IR/4 mg IR/4 mg IR/6 mg CR-RLS","deltaMin":5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":9},"locations":{"siteCount":30,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":52},"commonTop":["Headache","Nausea","Pain in extremity","Restless legs syndrome","Dizziness"]}}